Monitor the ICCBH 2026 presentation on June 28 for any unexpected efficacy or safety signals that could move the stock. The PROPEL 3 data has already been disclosed, this is a conference re-presentation, not a new catalyst. No trade action warranted based on this press release alone.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 22 $68.92entry
- T+1 · 5mo ago −0.42%α +1.03% · $68.63
- T+5 · 5mo ago +1.92%α +3.98% · $70.24
- T+20 · 4mo ago +18.08%α +18.23% · $81.38
- T+60 · 2mo ago −0.77%α −2.52% · $68.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BridgeBio announced additional positive data from the Phase 3 PROPEL 3 study of oral infigratinib in achondroplasia will be presented at ICCBH 2026, alongside other skeletal dysplasia and ADH1 data. This is a routine pipeline update with no new regulatory or commercial catalyst, the data was previously disclosed and the presentation is a conference update, not a new approval or trial result.
Key Facts
- Positive data from PROPEL 3 Phase 3 study of oral infigratinib in achondroplasia to be presented in late-breaking oral at ICCBH 2026 on June 28.
- Additional presentations include quality-of-life findings from PROPEL observational study, Phase 2/2b design for children under 3, and ADH1 CLARIFY study poster.
- No new regulatory filing, approval, or commercial milestone announced, this is a conference data presentation update.
Financial Impact
No financial figures disclosed; pipeline update with no immediate revenue or cost impact.
Risk Factors
- Conference presentations rarely move stock unless they contain material new data not previously disclosed, this appears to be a re-presentation of known PROPEL 3 results.
- No timeline for regulatory submission or approval of infigratinib in achondroplasia was provided.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3315189 |
Track record
38 reports on BBIO
10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers